Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Summary

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

Timeline

Start

2020-07-01

Primary completion

2025-06-04

Completion

2026-04

Outcome

Met primary endpoint

release “Both the INSPIRE -1 and INSPIRE-2 studies achieved the primary endpoint” sunpharma.com ↗

Drugs

Indications